Passively Targeted Curcumin-Loaded PEGylated PLGA Nanocapsules for Colon Cancer Therapy In Vivo

Overview

Journal Small

Date 2015 Jul 4

PMID 26140363

Citations 27

Authors

Rebecca Klippstein

Julie Tzu-Wen Wang

Riham I El-Gogary

Jie Bai

Falisa Mustafa

Noelia Rubio

Sukhvinder Bansal

Wafa T Al-Jamal

Khuloud T Al-Jamal

Affiliations

Soon will be listed here.

Abstract

Clinical applications of curcumin for the treatment of cancer and other chronic diseases have been mainly hindered by its short biological half-life and poor water solubility. Nanotechnology-based drug delivery systems have the potential to enhance the efficacy of poorly soluble drugs for systemic delivery. This study proposes the use of poly(lactic-co-glycolic acid) (PLGA)-based polymeric oil-cored nanocapsules (NCs) for curcumin loading and delivery to colon cancer in mice after systemic injection. Formulations of different oil compositions are prepared and characterized for their curcumin loading, physico-chemical properties, and shelf-life stability. The results indicate that castor oil-cored PLGA-based NC achieves high drug loading efficiency (≈18% w(drug)/w(polymer)%) compared to previously reported NCs. Curcumin-loaded NCs internalize more efficiently in CT26 cells than the free drug, and exert therapeutic activity in vitro, leading to apoptosis and blocking the cell cycle. In addition, the formulated NC exhibits an extended blood circulation profile compared to the non-PEGylated NC, and accumulates in the subcutaneous CT26-tumors in mice, after systemic administration. The results are confirmed by optical and single photon emission computed tomography/computed tomography (SPECT/CT) imaging. In vivo growth delay studies are performed, and significantly smaller tumor volumes are achieved compared to empty NC injected animals. This study shows the great potential of the formulated NC for treating colon cancer.

Citing Articles

Development, Characterization, and Evaluation of Chi-Tn mAb-Functionalized DOTAP-PLGA Hybrid Nanoparticles Loaded with Docetaxel for Lung Cancer Therapy.

Castro A, Pittini A, Berois N, Faccio R, Miranda P, Mombru A Pharmaceutics. 2025; 17(2).

PMID: 40006531 PMC: 11859453. DOI: 10.3390/pharmaceutics17020164.

Application and potential value of curcumin in prostate cancer: a meta-analysis based on animal models.

Wang S, Zhang F, Chen J Front Pharmacol. 2024; 15:1379389.

PMID: 38783940 PMC: 11111872. DOI: 10.3389/fphar.2024.1379389.

Poly(d,l-lactide--glycolide) Surface-Anchored Biotin-Loaded Irinotecan Nanoparticles for Active Targeting of Colon Cancer.

Giram P, Nimma R, Bulbule A, Yadav A, Gorain M, Venkata Radharani N ACS Omega. 2024; 9(3):3807-3826.

PMID: 38284072 PMC: 10809773. DOI: 10.1021/acsomega.3c07833.

Recent Insights into Nanotechnology in Colorectal Cancer.

Asareh Zadegan Dezfuli A, Abu-Elghait M, Salem S Appl Biochem Biotechnol. 2023; 196(7):4457-4471.

PMID: 37751009 DOI: 10.1007/s12010-023-04696-3.

Preservation of Fresh-Cut 'Maradol' Papaya with Polymeric Nanocapsules of Lemon Essential Oil or Curcumin.

Job Galindo-Perez M, Martinez-Acevedo L, Vidal-Romero G, Serrano-Mora L, de la Luz Zambrano-Zaragoza M Polymers (Basel). 2023; 15(17).

PMID: 37688140 PMC: 10489897. DOI: 10.3390/polym15173515.

References

Jambhrunkar S, Qu Z, Popat A, Yang J, Noonan O, Acauan L . Effect of surface functionality of silica nanoparticles on cellular uptake and cytotoxicity. Mol Pharm. 2014; 11(10):3642-55. DOI: 10.1021/mp500385n. View

Basnet P, Skalko-Basnet N . Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. 2011; 16(6):4567-98. PMC: 6264403. DOI: 10.3390/molecules16064567. View

Yallapu M, Jaggi M, Chauhan S . Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 2011; 17(1-2):71-80. PMC: 3259195. DOI: 10.1016/j.drudis.2011.09.009. View

Mukerjee A, Vishwanatha J . Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 2009; 29(10):3867-75. View

Lu W, Qin Y, Yang C, Li L, Fu Z . Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo. Clinics (Sao Paulo). 2013; 68(5):694-701. PMC: 3654338. DOI: 10.6061/clinics/2013(05)18. View

Punfa W, Suzuki S, Pitchakarn P, Yodkeeree S, Naiki T, Takahashi S . Curcumin-loaded PLGA nanoparticles conjugated with anti- P-glycoprotein antibody to overcome multidrug resistance. Asian Pac J Cancer Prev. 2014; 15(21):9249-58. DOI: 10.7314/apjcp.2014.15.21.9249. View

Mastrobattista , KONING , Storm . Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev. 2000; 40(1-2):103-127. DOI: 10.1016/s0169-409x(99)00043-5. View

Duan J, Zhang Y, Han S, Chen Y, Li B, Liao M . Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm. 2010; 400(1-2):211-20. DOI: 10.1016/j.ijpharm.2010.08.033. View

K Jayaprakasha G, Jagan Mohan Rao L, Sakariah K . Improved HPLC method for the determination of curcumin, demethoxycurcumin, and bisdemethoxycurcumin. J Agric Food Chem. 2002; 50(13):3668-72. DOI: 10.1021/jf025506a. View

10.

Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y . Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS One. 2012; 7(3):e32616. PMC: 3293842. DOI: 10.1371/journal.pone.0032616. View

11.

Gou M, Men K, Shi H, Xiang M, Zhang J, Song J . Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale. 2011; 3(4):1558-67. DOI: 10.1039/c0nr00758g. View

12.

Anand P, Nair H, Sung B, Kunnumakkara A, Yadav V, Tekmal R . Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol. 2009; 79(3):330-8. PMC: 3181156. DOI: 10.1016/j.bcp.2009.09.003. View

13.

Khalil N, do Nascimento T, Casa D, Dalmolin L, Mattos A, Hoss I . Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces. 2012; 101:353-60. DOI: 10.1016/j.colsurfb.2012.06.024. View

14.

Bouchemal K, Briancon S, Perrier E, Fessi H . Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharm. 2004; 280(1-2):241-51. DOI: 10.1016/j.ijpharm.2004.05.016. View

15.

Mulik R, Monkkonen J, Juvonen R, Mahadik K, Paradkar A . ApoE3 mediated polymeric nanoparticles containing curcumin: apoptosis induced in vitro anticancer activity against neuroblastoma cells. Int J Pharm. 2012; 437(1-2):29-41. DOI: 10.1016/j.ijpharm.2012.07.062. View

16.

Lopez-Lazaro M . Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res. 2008; 52 Suppl 1:S103-27. DOI: 10.1002/mnfr.200700238. View

17.

Ghalandarlaki N, Alizadeh A, Ashkani-Esfahani S . Nanotechnology-applied curcumin for different diseases therapy. Biomed Res Int. 2014; 2014:394264. PMC: 4066676. DOI: 10.1155/2014/394264. View

18.

Jasanada F, Urizzi P, Souchard J, Le Gaillard F, Favre G, Nepveu F . Indium-111 labeling of low density lipoproteins with the DTPA-bis(stearylamide): evaluation as a potential radiopharmaceutical for tumor localization. Bioconjug Chem. 1996; 7(1):72-81. DOI: 10.1021/bc950073l. View

19.

Karunagaran D, Rashmi R, Santhosh Kumar T . Induction of apoptosis by curcumin and its implications for cancer therapy. Curr Cancer Drug Targets. 2005; 5(2):117-29. DOI: 10.2174/1568009053202081. View

20.

Sharma R, Euden S, Platton S, Cooke D, Shafayat A, Hewitt H . Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004; 10(20):6847-54. DOI: 10.1158/1078-0432.CCR-04-0744. View